Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.15 | 3.60% | 0.04 |
BOLT closed down 3.48 percent on Wednesday, April 17, 2024, on 52 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 3.60% | |
| 180 Bearish Setup | Bearish Swing Setup | 3.60% | |
| Narrow Range Bar | Range Contraction | 3.60% | |
| Wide Bands | Range Expansion | 3.60% | |
| Oversold Stochastic | Weakness | 3.60% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Hammer Candlestick | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% |
| Alert | Time |
|---|---|
| Rose Above 200 DMA | about 1 hour ago |
| Up 3% | about 1 hour ago |
| Up 2% | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| 200 DMA Resistance | about 2 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.03 |
| 52 Week Low | 0.84 |
| Average Volume | 143,239 |
| 200-Day Moving Average | 1.13 |
| 50-Day Moving Average | 1.20 |
| 20-Day Moving Average | 1.26 |
| 10-Day Moving Average | 1.24 |
| Average True Range | 0.08 |
| RSI (14) | 39.39 |
| ADX | 23.11 |
| +DI | 18.86 |
| -DI | 23.90 |
| Chandelier Exit (Long, 3 ATRs) | 1.31 |
| Chandelier Exit (Short, 3 ATRs) | 1.33 |
| Upper Bollinger Bands | 1.47 |
| Lower Bollinger Band | 1.05 |
| Percent B (%b) | 0.14 |
| BandWidth | 33.01 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0283 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.17 | ||||
| Resistance 3 (R3) | 1.18 | 1.16 | 1.16 | ||
| Resistance 2 (R2) | 1.16 | 1.15 | 1.16 | 1.16 | |
| Resistance 1 (R1) | 1.14 | 1.14 | 1.13 | 1.13 | 1.15 |
| Pivot Point | 1.12 | 1.12 | 1.12 | 1.12 | 1.12 |
| Support 1 (S1) | 1.10 | 1.11 | 1.09 | 1.09 | 1.07 |
| Support 2 (S2) | 1.08 | 1.10 | 1.08 | 1.06 | |
| Support 3 (S3) | 1.06 | 1.08 | 1.06 | ||
| Support 4 (S4) | 1.05 |
